|
Bioventix PLC on Monday cited headwinds in its historic core business as it announced a dividend cut amid a decline in annual profit and turnover. In response, Bioventix shares were down 20% to 1,855.00 pence on Monday afternoon in London. The London-based biotechnology company said turnover declined by 3.6% to £13.1 million in the financial year that ended June 30 from £13.6 million the year prior. Pretax profit declined 4.8% to £10.1 million from £10.6 million. BioVentix declared a second interim dividend of 80p per share, down 8.0% from 87p a year ago, to give a total dividend for the year of 150p per share, down 3.2% from 155p in financial 2024. ‘This year has been particularly noteworthy as our historic core business has faced some challenges in downstream markets, particularly in China,’ the company noted. Bioventix expects a ‘modest decline’ in revenue during the current financial year due to ‘a number of headwinds remaining within the historic core business’. Despite this, it said: ‘Our research and commercialisation of antibodies in the field of neurology has experienced significant progress. The vision of our customers for growth in this exciting field together with the performance of our antibodies at many of our customers points to future success in this area.’ Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
